drugset / Trial / NCT04903652
Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is a single-center, single-arm, prospective phase II clinical study, which mainly evaluates the efficacy and safety of pyrotinib maleate combined with oral vinorelbine in the treatment of HER2-positive advanced breast cancer.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2022-02-01
- Completion
- 2022-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pyrotinib | Small molecule | 400 mg | Oral |
| Subject | Vinorelbine | Small molecule | 40 mg | Oral |